Cargando…

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk

Detalles Bibliográficos
Autores principales:	Jarcuska, Peter, Abdel-Razik, Ahmed, Flisiak, Robert, Singh, Ram B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241355/ https://www.ncbi.nlm.nih.gov/pubmed/30519548 http://dx.doi.org/10.1155/2018/7369314

Ejemplares similares

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Shear-wave elastography for evaluation of hepatic stiffness in chronic viral hepatitis B and C
por: Martonik, Diana, et al.
Publicado: (2023)

Effects of Metabolic Syndrome on Fibrosis in Chronic Viral Hepatitis
por: Yoon, Harry, et al.
Publicado: (2013)

Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia
por: Drazilova, Sylvia, et al.
Publicado: (2016)

Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids
por: Bäck, Magnus, et al.
Publicado: (2023)

T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Fisicaro, Paola, et al.
Publicado: (2022)

Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies
por: Seto, Wai-Kay
Publicado: (2019)

Pathophysiological Insights into Cardiovascular Health in Metabolic Syndrome
por: Zhang, Yingmei, et al.
Publicado: (2012)

Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Flisiak, Robert, et al.
Publicado: (2021)

Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis
por: Maggi, Paolo, et al.
Publicado: (2022)

How close are we to hepatitis C virus elimination in Central Europe?
por: Flisiak, Robert, et al.
Publicado: (2020)

The Roma Population Living in Segregated Settlements in Eastern Slovakia Has a Higher Prevalence of Metabolic Syndrome, Kidney Disease, Viral Hepatitis B and E, and Some Parasitic Diseases Compared to the Majority Population
por: Macejova, Zelmira, et al.
Publicado: (2020)

VIRAL HEPATITIS, THE BATTLE CONTINUES
por: Al-Freihi, Hussein M.
Publicado: (1997)

Long-Term Suppression of Viral Replication in Chronic Hepatitis B: Outcomes and Future Directions
por: Shim, Jae-Jun
Publicado: (2015)

National viral hepatitis control program in India: Call for update
por: Pandey, Pragya, et al.
Publicado: (2023)

IGF-1 and Cardiovascular and Non-Cardiovascular Mortality Risk in Patients with Chronic Kidney Disease: A Model of “Malnutrition-Inflammation-Atherosclerosis Syndrome”
por: Shimabukuro, Michio
Publicado: (2022)

Metabolic, Endocrine, and Cardiovascular Risks in Children with Overnutrition and Undernutrition
por: Calcaterra, Valeria, et al.
Publicado: (2022)

Combating the wrath of viral hepatitis in India
por: Satsangi, Sandeep, et al.
Publicado: (2016)

Virale Hepatitis – ein versteckter Killer
por: Hildt, Eberhard
Publicado: (2022)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Metabolic Syndrome and Cardiovascular Risk Factors in Obese Adolescent
por: Mansour, Manal, et al.
Publicado: (2016)

Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
por: Kim, Eun Soo
Publicado: (2017)

Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2015)

Metabolic syndrome and chronic obstructive pulmonary disease
por: Koul, Parvaiz A
Publicado: (2016)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Viral hepatitis in Saudi Arabia: An unfinished story
por: Abdo, Ayman A., et al.
Publicado: (2015)

Metabolic syndrome and cardiovascular risk
por: Alshehri, Abdullah M.
Publicado: (2010)

Molecular Mechanism of Chronic Viral and Non-Viral Liver Diseases
por: Kanda, Tatsuo
Publicado: (2023)

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.
por: Kim, Won
Publicado: (2019)

Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance
por: Chang, Ming-Ling, et al.
Publicado: (2017)

Is Klotho deficiency independently associated with cardiovascular risk in chronic kidney disease?
por: Bae, Eun Hui
Publicado: (2016)

Zinc Oxide Nanoparticles and Vitamin C Ameliorate Atrazine-Induced Hepatic Apoptosis in Rat via CYP450s/ROS Pathway and Immunomodulation
por: Mohammed, Eman T., et al.
Publicado: (2023)

Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis C
por: Rogalska-Taranta, Magdalena, et al.
Publicado: (2017)

Metabolic syndrome leading to chronic kidney disease: An emerging threat
por: Bandgar, Tushar R., et al.
Publicado: (2012)

Vitamin D, the autonomic nervous system, and cardiovascular risk
por: Mann, Michelle Catherine, et al.
Publicado: (2015)

World Hepatitis Day in 2022: Challenges of Viral Hepatitis Elimination in Elongated COVID-19 Pandemic
por: Pourkarim, Mahmoud Reza
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_omhb2iqjtgpclf1avf7n37kqgb